

META HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration 198804700N)

UPDATE ON SALE OF WHOLLY-OWNED SUBSIDIARIES

The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”) refers to the Company’s announcement on 21 November 2023 and the Company’s circular to shareholders dated 7 December 2023 (the “**Circular**”), in relation to the sale (the “**Sale**”) of the entire issued and paid-up share capital of MCE Technologies (Suzhou) Co., Ltd. (the “**MCE Suzhou**”), as well as the Company’s announcement dated 22 December 2023 in relation to the results of the extraordinary general meeting held on 22 December 2023 where the shareholders of the Company approved the Sale.

Unless otherwise defined or required by the context, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Circular.

The Board is pleased to announce that the First Instalment of Equity Consideration of RMB450,000 and the consideration for the Proposed Transfer of RM50,000 have been paid by the Purchaser to MCE Holdings. Accordingly, MCE Holdings and the Purchaser are co-operating with MCE Suzhou to complete the Registration Procedures in accordance with the SPA.

MCE Suzhou and MCE Shanghai (a wholly-owned subsidiary of MCE Suzhou) shall cease to be subsidiaries of the Company and the Group upon the completion of the Registration Procedures.

The Company will make the appropriate announcement(s) as and when there are further material developments on the Proposed Transactions.

Shareholders and potential investors of the Company should note that there is no certainty or assurance that the Proposed Transactions will proceed to completion or that no further changes will be made to the terms thereof. Shareholders and potential investors of the Company are advised to read this announcement and any past and future announcements by the Company carefully and exercise caution when dealing with the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisors if they have any doubt about the actions they should take or when dealing with the securities of the Company.

BY ORDER OF THE BOARD

Lee Wei Hsiung
Company Secretary
18 January 2024

*This announcement has been prepared by Meta Health Limited (the “**Company**”) and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the “**Sponsor**”), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.